Breast cancer was the fifth-most common malignancy among women during 2003-2004. Incidence of invasive breast cancer was approximately 6 percent of all cancers among all women, and incidence of invasive breast cancer tended to be similar regardless of race, ethnicity, age, sex, or education.
Women diagnosed with [breast cancer](https://www.withpower.com/clinical-trials/breast-cancer) represent a large subpopulation of breast cancer patients who are less likely to be satisfied with their lives than women with other kinds of cancer.
In contrast to the general public, a significant part of the scientific community is skeptical about the possibility of curative breast cancer treatments, and believes that any improvements in patient survival are most likely due to advances in medical practice and improved treatment of women at recurrence.
Patients with [breast cancer](https://www.withpower.com/clinical-trials/breast-cancer) who are undergoing treatment usually receive multiple medications to treat both the cancer (chemotherapy and/or hormone therapy) and any related illnesses or symptoms. Patients may also receive drugs (antibiotics) to help prevent bacterial infections. There are no medications that have been shown to slow or stop breast cancer tumours from growing, but many commonly prescribed medications have an unknown risk for slowing or stopping the growth of breast cancer tumours.
The most common clinical presentation of [breast cancer](https://www.withpower.com/clinical-trials/breast-cancer) is lump detected on a self-examination, followed by an abnormal mammogram. More than 10 years were needed before the lump developed to a breast neoplasm. A significant fraction of patients underwent mammographic screening. There was no correlation between self-reported breast or other cancer screening and the presence or absence of breast nodules, breast masses, lump or nipple discharge.
We conclude that [18F]fluorthanatrace has been a successful radiotracer in this PET-CT based study, and provides valuable insight in terms of image quality, patient selection and study design.
The occurrence of breast cancer is highly age and family history dependent. The odds may be increased by smoking, alcohol intake, diabetes and obesity, and by the use of hormonally active drugs and tobacco to treat acne and other diseases.
The side effects of [18f]fluorthanatrace are similar to those of the parent radiolabelled compound and are mostly dose-dependent. [18f]fluorthanatrace is therefore used as an analogue in order to avoid the drawbacks associated with the use of (111)In. However, the side effects of the drug are still similar to those observed in conventional (125)In-fluoroscopy, and more subtle but nonetheless significant correlations are still found with certain patient-specific traits. Moreover, some side effects of [18f]fluorthanatrace are found to disappear under other conditions - these side effects are currently being studied and, if applicable, might be exploited for potential clinical uses.
[F]-fluorothanatride, as a result of its ability to block nuclear uptake of thymidine, is not an effective anticancer agent since it binds to and inhibits the DNA polymerase II enzyme, without any antitumor activity.
Although cancer cells were undetectable in the sample of the primary tumor, this was largely as a result of cancer cells passing into the lymph system. The primary tumor was not detectable in 10 (22%) of 41 patients, and was detectable in only 7 (16%) of 45 tumors.
A primary (idiopathic) cause of [breast cancer](https://www.withpower.com/clinical-trials/breast-cancer) may be suggested by the early onset of this type of cancer, family history of breast cancer, and the presence of benign breast abnormalities in patients with breast cancer. It is also possible for breast cancer to occur in association with other conditions, such as those of the connective tissue and bone, as well as those involving hormones.